I. Gardner
Impact in
- Pharmacology top 2%
- Pharmacogenetics and Drug Metabolism
- Antibiotics Pharmacokinetics and Efficacy
- Drug-Induced Hepatotoxicity and Protection
Papers in
-
- Receptor Mechanisms and Signaling 2
- Biochemical and Molecular Research 2
- Oncology 4
- Drug Transport and Resistance Mechanisms 3
- Co-authors
- Masoud Jamei (7 shared papers)Lisa M. Almond (3 shared papers)Amin Rostami‐Hodjegan (2 shared papers)Susan Wong (2 shared papers)Jane R. Kenny (2 shared papers)W. Alderton (2 shared papers)Frances M. Richards (1 shared paper)Stéphane Berghmans (2 shared papers)
- Journals
- Xenobiotica (5 papers)CPT Pharmacometrics & Systems Pharmacology (2 papers)Toxicology Letters (2 papers)Clinical Pharmacology & Therapeutics (1 paper)Current Opinion in Toxicology (1 paper)
- Partner nations
- United KingdomUnited StatesGermany
In The Last Decade
I. Gardner
13 papers receiving 498 citations
Peers
Comparison fields: 5 of 88
- Pharmacology 195
- Health, Toxicology and Mutagenesis 55
- Pharmacology 67
- Oncology 103
- Cell Biology 56
Countries citing papers authored by I. Gardner
This map shows the geographic impact of I. Gardner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Gardner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Gardner more than expected).
Fields of papers citing papers by I. Gardner
This network shows the impact of papers produced by I. Gardner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Gardner. The network helps show where I. Gardner may publish in the future.
Co-authors
The 25 scholars most cited alongside I. Gardner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2010 | 94 | |
| 2 | 2016 | 91 | |
| 3 | 2013 | 86 | |
| 4 | 2015 | 64 | |
| 5 | 2008 | 46 | |
| 6 | 2018 | 44 | |
| 7 | 2014 | 27 | |
| 8 | Bioactivation and covalent binding of hydroxyfluperlapine in human neutrophils: implications for fluperlapine-induced agranulocytosis. | 2000 | 20 |
| 9 | 1995 | 15 | |
| 10 | 2009 | 10 | |
| 11 | 2019 | 7 | |
| 12 | 2008 | 5 | |
| 13 | 2008 | 1 | |
| 14 | 2025 | 0 | |
| 15 | 2025 | 0 | |
| 16 | 2016 | 0 | |
| 17 | 2018 | 0 |
About I. Gardner
I. Gardner is a scholar working on Molecular Biology, Oncology, Computational Theory and Mathematics, Pharmacology and Small Animals, having authored 17 papers that have together received 510 indexed citations. Recurring topics across this work include Computational Drug Discovery Methods (4 papers), Pharmacogenetics and Drug Metabolism (4 papers), Animal testing and alternatives (3 papers), Drug Transport and Resistance Mechanisms (3 papers), Pharmacological Effects and Toxicity Studies (2 papers), Receptor Mechanisms and Signaling (2 papers), Effects and risks of endocrine disrupting chemicals (2 papers) and Biochemical and Molecular Research (2 papers). The work is most often cited by research in Pharmacology (195 citations), Health, Toxicology and Mutagenesis (55 citations), Pharmacology (67 citations), Oncology (103 citations) and Cell Biology (56 citations). I. Gardner has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Masoud Jamei, Lisa M. Almond, Amin Rostami‐Hodjegan, Susan Wong, Jane R. Kenny, W. Alderton, Frances M. Richards, Stéphane Berghmans, Zoe Golder and Angeleen Fleming. Their work appears in journals such as Xenobiotica, CPT Pharmacometrics & Systems Pharmacology, Toxicology Letters, Clinical Pharmacology & Therapeutics and Current Opinion in Toxicology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.